Spinal Cord Injury Axon Regrowth Barriers and Therapies
Key Takeaways
- In spinal cord injury, failed axonal regeneration reflects both the inhibitory lesion microenvironment and the reduced intrinsic growth capacity of mature neurons.
- Glial scarring is biphasic, with a protective role during the first 0–2 weeks after injury and a predominantly inhibitory, CSPG-rich barrier after more than 2 weeks.
- Myelin-associated inhibitors and CSPGs are major extracellular brakes on regrowth that converge through RhoA/ROCK-related signaling to promote growth cone collapse and suppress axonal elongation.
- Translational maturity remains uneven across regenerative strategies, and phase-informed combination approaches are presented as a likely future direction rather than a proven clinical solution.
In the review, the authors frame spinal cord injury (SCI) as a central nervous system (CNS) disorder with a reported incidence of 8–83 cases per million, 250,000–500,000 new cases annually worldwide, and more than 2.7 million people affected globally. The narrative review is organized around two domains: barriers to axonal regeneration and strategies intended to overcome them. It explicitly contrasts lesion-environment inhibition, including myelin-associated inhibitors (MAIs) and chondroitin sulfate proteoglycans (CSPGs), with declining intrinsic neuronal growth capacity while examining biological targets, injury-stage relevance, available preclinical and clinical evidence, and unresolved translational barriers.
The review presents regeneration failure as a network-level problem in which extrinsic and intrinsic barriers converge rather than as a single lesion-site obstacle. It describes glial scarring as beneficial during the acute to subacute phase spanning 0–2 weeks after injury, when it helps contain the lesion, limit inflammation, restore the blood-spinal cord barrier, and provide neurotrophic support, but as a dense inhibitory matrix during the chronic phase after more than 2 weeks. Nogo, myelin-associated glycoprotein, oligodendrocyte myelin glycoprotein, and CSPGs are identified as major extracellular inhibitors that converge on RhoA and Rho-associated protein kinase signaling, while impaired axonal transport, lower receptor expression, and constrained PI3K/Akt/mTOR- and JAK/STAT-linked growth signaling further limit regrowth. The therapeutic classes reviewed include scar modulation, MAI neutralization, CSPG targeting, supportive microenvironment reconstruction, cell transplantation, biomaterial scaffolds, intrinsic growth activation, and neuromodulation.
Across the therapeutic frontiers for axonal regeneration after spinal cord injury, scar modulation, scaffold strategies, gene-based approaches, CSPG-directed strategies, intrinsic growth activation, magnetic stimulation, ultrasound stimulation, and optogenetic approaches are described as remaining largely preclinical or early translational, whereas anti-Nogo-A therapy, NgR1-targeted inhibition, RhoA/ROCK inhibition, mesenchymal stem cells, oligodendrocyte progenitor cells, and selected growth-factor approaches have entered clinical investigation. The review says anti-Nogo-A antibodies appeared most effective from within hours to approximately 14 days after injury; NG101 did not improve upper-limb motor function in the overall acute cervical SCI cohort, AXER-204 showed a favorable safety profile and potential benefit in chronic incomplete SCI, BA-210 improved motor scores in phase I/IIa testing, and VX-210 failed to significantly improve function in phase IIb/III testing. It also describes transcutaneous spinal cord stimulation (tSCS) and spinal cord epidural stimulation (scES) used with rehabilitation as having relatively more clinical evidence for functional improvement than several other regenerative modalities.
The authors describe translation as being constrained by therapeutic timing, lesion-site delivery, biosafety, scalability, endpoint sensitivity, and the biological heterogeneity of human SCI relative to standardized rodent models. They also note therapy-specific barriers, including thermal-stability and immune-response concerns for bacterial chondroitinase ABC, off-target and viral immunogenicity concerns for gene-transfer approaches, long-term biosafety, biodegradation, integration, and manufacturing challenges for scaffold strategies, and the broad cellular effects of intrinsic growth activation on proliferation, inflammation, and tumor-related signaling. The review cautions that functional improvement with neuromodulation should not be equated with proven anatomical axonal regeneration because gains may reflect spared-circuit excitability or plasticity, and it presents phase-informed combinations as a biologically grounded translational framework rather than a treatment algorithm.
The authors conclude that SCI repair is a multilevel problem involving convergent inhibitory signaling and insufficient activation of intrinsic growth programs, with no single therapeutic class identified as ready for routine care. They add that future progress will likely depend on phase-informed, biologically rational combinations supported by stronger translational models and larger randomized trials.
Clinician Questions
What does the review identify as the main reasons axons fail to regrow after spinal cord injury?
Axonal regeneration after spinal cord injury is described as being limited by both extrinsic inhibitory factors in the post-injury lesion environment and reduced intrinsic growth capacity of mature neurons, including glial scarring, MAIs, CSPGs, insufficient growth-promoting factors, impaired axonal transport, reduced receptor expression, and constrained intrinsic growth signaling.
How does glial scar biology change over time after spinal cord injury?
During the acute to subacute period, spanning 0–2 weeks after spinal cord injury, glial scarring is described as helping contain the lesion, limit inflammation, restore the blood-spinal cord barrier, and provide neurotrophic support, whereas after more than 2 weeks the scar becomes a dense CSPG-rich physical and biochemical barrier to axonal regrowth.
Which molecules are highlighted as major extracellular inhibitors of axonal regeneration after spinal cord injury?
The review highlights the myelin-associated inhibitors Nogo, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein, along with CSPGs in the glial scar, and says these signals converge on RhoA/ROCK-related pathways that promote growth cone collapse and suppress axonal elongation.
Which spinal cord injury regenerative strategies appear furthest along clinically in this review?
The review describes translational maturity as uneven, with many scaffold, gene-based, CSPG-directed, intrinsic-growth, magnetic, ultrasound, and optogenetic approaches still mainly preclinical or early translational, while anti-Nogo-A, NgR1-targeted inhibition, RhoA/ROCK inhibition, mesenchymal stem cells, oligodendrocyte progenitor cells, and selected growth-factor approaches have entered clinical investigation. It also says tSCS and scES combined with rehabilitation have relatively more clinical evidence for functional improvement, while noting that functional gains are not the same as proven anatomical axonal regeneration.